At baseline (day 1), there were no notable differences in fasting serum concentrations of BAs (total), FGF-19 or FGF-21 between the volixibat and placebo groups in either the HV or T2DM cohorts (Table 3). The gene discussed is FGF19; the disease is type 2 diabetes mellitus.